AbbVie (NY:ABBV)

265.76 +2.94 (+1.12%)

Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Small- To Mid-Cap Biotech Trades Poised For Gains ↗

February 01, 2025

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...

Via Talk Markets

Topics ETFs Stocks / Equities

Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades. ↗

February 01, 2025

Via The Motley Fool

What's going on in today's session: S&P500 movers ↗

January 31, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

AbbVie (NYSE:ABBV) Posts Better-Than-Expected Sales In Q4, Stock Soars

January 31, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share...

Via StockStory

Why AbbVie Stock Is Jumping Today ↗

January 31, 2025

Via The Motley Fool

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today ↗

January 30, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts ↗

January 28, 2025

Via Benzinga

$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today ↗

January 24, 2025

Via Benzinga

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗

January 31, 2025

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

Via Benzinga

AbbVie (ABBV) Q4 2024 Earnings Call Transcript ↗

January 31, 2025

ABBV earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Top S&P500 movers in Friday's session ↗

January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Tech Stocks Rally, S&P 500 Flirts With Records, Gold Extends All-Time Highs: What's Driving Markets Friday? ↗

January 31, 2025

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands...

Via Benzinga

Topics Stocks

Unpacking the Latest Options Trading Trends in AbbVie ↗

January 24, 2025

Via Benzinga

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

January 31, 2025

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

Via MarketBeat

Topics Intellectual Property

AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens ↗

January 31, 2025

The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.

Via Stocktwits

Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗

January 31, 2025

Via Benzinga

AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline ↗

January 31, 2025

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.

Via Benzinga

Topics Earnings

5 Top Stocks to Buy in February 2025 ↗

January 31, 2025

All of them have great upside.

Via The Motley Fool

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate ↗

January 31, 2025

The company now expects Skyrizi and Rinvoq to bring in $31 billion in combined sales in 2027.

Via Investor's Business Daily

US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact ↗

January 31, 2025

US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.

Via Benzinga

Earnings Scheduled For January 31, 2025 ↗

January 31, 2025

Via Benzinga

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? ↗

January 30, 2025

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Via Benzinga

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One. ↗

January 28, 2025

Via The Motley Fool

Why AbbVie Stock Popped While the Market Flopped on Monday ↗

January 27, 2025

Via The Motley Fool

AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive ↗

January 27, 2025

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors.

Via Benzinga

Biotech And Healthcare Stocks Poised For Gains Ahead ↗

January 27, 2025

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

Via Talk Markets

Topics ETFs Stocks / Equities

Is AbbVie Stock a Buy? ↗

January 24, 2025

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Via The Motley Fool

Topics Intellectual Property

Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗

January 21, 2025

Via The Motley Fool

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.